BIOXYTRAN INC Reported Earnings

BIOXYTRAN INC (BIXT) reported a loss of $0.01 per share on revenue of $0.00 million for the . .

BioXyTran Inc. is a biotechnology company. It develops anti-necrosis drugs to treat medical conditions resulting from ischemia. The company's product pipeline consists of BXT-25 and BXT-252 which are in clinical stage. BioXyTran Inc. is based in Newton, United States.